$2.05
-0.04 (-1.91%)
Open$2.07
Previous Close$2.09
Day High$2.08
Day Low$1.95
52W High$64.12
52W Low$1.36
Volume—
Avg Volume118.9K
Market Cap4.48M
P/E Ratio—
EPS$-51.65
SectorBiotechnology
Analyst Ratings
Strong Buy
6 analysts
Price Target
+1,821.5% upside
Current
$2.05
$2.05
Target
$39.39
$39.39
$26.66
$39.39 avg
$54.88
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 1.03M | 1.06M | 807.5K |
| Net Income | -278,352 | -347,095 | -248,556 |
| Profit Margin | -27.1% | -32.7% | -30.8% |
| EBITDA | -433,012 | -468,823 | -342,942 |
| Free Cash Flow | -135,403 | -181,532 | -119,491 |
| Rev Growth | +14.1% | -2.0% | +8.2% |
| Debt/Equity | 0.22 | 0.23 | 0.23 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $266.28 | +0.73% | 74.3 | 468.50B |
| AMGN | Amgen Inc | $418.13 | +0.85% | 25.1 | 219.78B |
| GILD | Gilead Sciences Inc | $152.21 | +0.85% | — | 185.02B |
| VRTX | Vertex Pharmaceuticals Inc | $527.67 | +0.28% | 30.5 | 134.17B |
| REGN | Regeneron Pharmaceuticals | $752.25 | -4.54% | 18.8 | 81.31B |
| ALNY | Alnylam Pharmaceuticals Inc | $255.36 | -0.23% | 41.4 | 33.44B |